-
25-10-2018, 12:51 PM
#16621
Originally Posted by Balance
Read between the lines - where is the Kaiser deal after 2 years now of negotiations (we only ever hear from PEB and how the deal is just around the corner - must be a long long long long corner!) and why does Johns Hopkins need to do a separate user program if Kaiser's stack up?
Remember - we are writing about PEB here! The company which promised everything (excitement, transformation, millions of customers and billions of revenue potential) but has delivered?
Isn't Miner's point that JH is doing a user program on Monitor, whereas Kaiser's was on Triage...? Is it conceivable that JH doesn't see the need to trial Triage because they have access to Kaiser's results...? Is it also possible that the delays with Kaiser are related to the LCD process, and now that it appears that the LCD process is actually moving forwards (hence the reimbursement rate being set), maybe the Kaiser corner is getting shorter...? Maybe... Maybe not...
-
25-10-2018, 01:25 PM
#16622
Originally Posted by Balance
Read between the lines - where is the Kaiser deal after 2 years now of negotiations (we only ever hear from PEB and how the deal is just around the corner - must be a long long long long corner!) and why does Johns Hopkins need to do a separate user program if Kaiser's stack up?
Remember - we are writing about PEB here! The company which promised everything (excitement, transformation, millions of customers and billions of revenue potential) but has delivered?
Try reading the lines and not whats between them.
Its not a separate "User Program", it is the establishment of clinical procedure, in their space (JH), around the adoption of Monitor.
Its about utilisation rather than verification that cxBladder Monitor works. They obviously already know that, probably courtesy of Kaiser, and they just have to figure where it fits best in their system.
Cant see their Urologists kicking up a stink as they will probably be on salary and the reduced requirement for theatre space will allow other waiting lists to be reduced.
-
25-10-2018, 02:13 PM
#16623
Originally Posted by Minerbarejet
Try reading the lines and not whats between them.
Its not a separate "User Program", it is the establishment of clinical procedure, in their space (JH), around the adoption of Monitor.
Its about utilisation rather than verification that cxBladder Monitor works. They obviously already know that, probably courtesy of Kaiser, and they just have to figure where it fits best in their system.
Cant see their Urologists kicking up a stink as they will probably be on salary and the reduced requirement for theatre space will allow other waiting lists to be reduced.
https://www.nzx.com/announcements/325306
Monitor? You are making assumptions - history tells us that one must never make any assumption with PEB!
-
25-10-2018, 02:22 PM
#16624
Originally Posted by Balance
From the Announcement that you so handily posted.
"An initial select group of Johns Hopkins urologists will use Cxbladder for patients under surveillance for the recurrence of bladder cancer. The commercial evaluation will allow John Hopkins’ urologists to evaluate and determine the best fit for Cxbladder within their clinical practice and provide data specific to their organization and patients.
Assumptions - I don't think so.
-
25-10-2018, 03:16 PM
#16625
Originally Posted by Minerbarejet
From the Announcement that you so handily posted.
"An initial select group of Johns Hopkins urologists will use Cxbladder for patients under surveillance for the recurrence of bladder cancer. The commercial evaluation will allow John Hopkins’ urologists to evaluate and determine the best fit for Cxbladder within their clinical practice and provide data specific to their organization and patients.
Assumptions - I don't think so.
You have replied my question for yourself!
-
25-10-2018, 05:08 PM
#16626
Oh well, I suppose they could use Detect, Triage or Resolve for surveillance of recurrence but that would be a bit daft if they have Monitor which is the one designed to cater for this circumstance.
If that is what you are getting at.
Still, funnier things have happened at sea, I suppose.
-
25-10-2018, 06:02 PM
#16627
Originally Posted by Minerbarejet
With a Kaiser/ Johns Hopkins collaboration on Cxbladder, specifically, if it exists, would it not be most likely that any shared data or information was sufficiently positive for Johns Hopkins to initiate their own appraisal of Monitor and how it can be utilised in their system?
Data came from somewhere for JH to take this step as it is a direct line into Monitor which has the potential to save the largest amounts.
Being non profit organisations both of these will be looking to cut costs where possible.
I cant see Kaiser at this point telling Pacific Edge to shove off.
Timeline of PEB's deal with Kaiser :
Nov 14th 2016 : "successfully completed its analysis of the data from the large scale Kaiser Permanente (Kaiser) User Programme with positive and compelling findings.
Aug 24th 2017 : "Kaiser .... we are now nearing the end of the negotiations on a commercial agreement"
Nov 29th 2017 : "Commercial negotiations are progressing positively with Kaiser Permanente"
April 19th 2018 : "Making good progress"
May 22th 2018 : "The commercial agreement continues to move forward"
-
25-10-2018, 06:35 PM
#16628
May the 22th? Thats a new one.
(Bet he changes it.)
Last edited by Minerbarejet; 25-10-2018 at 06:37 PM.
-
25-10-2018, 06:36 PM
#16629
-
01-11-2018, 11:42 AM
#16630
https://www.urotoday.com/recent-abst...ommentary.html
It cannot be that these Urologists are not aware of what CxBladder can do for their patients?
Simply cannot be!
Tags for this Thread
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks